Showing results (491-500 of 504) with videos related to
Sort By:
Pageof 51
Clinica Chimica Acta; International Journal of Clinical Chemistry|December 26, 2022
Evaluating the value of anti-SARS-CoV-2 antibody detection and neutralizing responses with euvirus: A population of 10776 close contacts in the epidemic of FujianYongbin Zeng, Caorui Lin, Can Liu, et al.Journal of Sport and Health Science|July 23, 2026
Guiding functional near-infrared spectroscopy research on sedentary behavior and brain healthJinming Li, Yanxia Chen, Yiming Tao, et al.Nature Communications|October 16, 2025
Methylation reference datasets from quartet DNA materials for benchmarking epigenome sequencingXiaorou Guo, Qingwang Chen, Yuanfeng Zhang, et al.Breast Cancer Research and Treatment|August 27, 2025
Transcriptomic and microenvironment characteristics of triple-negative breast cancer under three different neoadjuvant treatment regimensZhilin Liu, Zhen Liu, Miaozhou Wang, et al.International Journal of Clinical and Health Psychology : IJCHP|May 6, 2026
Timing of MVPA and psychosocial outcomes in adolescents with overweight/obesitySiyu Pan, Peng Wang, Yiming Tao, et al.Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|March 6, 2026
DCAF13 Safeguards Hematopoietic Stem Cells via RRS1-Regulated Ribosome BiogenesisMengke Li, Yuxin Wu, Shuai Zhou, et al.ACS Chemical Neuroscience|March 25, 2025
Application of Deuterium in an M1 Positive Allosteric Modulator Back-Up Program: The Discovery of VU6045422Julie L Engers, Jinming Li, Changho Han, et al.Signal Transduction and Targeted Therapy|February 6, 2025
Neoadjuvant apatinib addition to sintilimab and carboplatin-taxane based chemotherapy in patients with early triple-negative breast cancer: the phase 2 NeoSAC trialGuoshuang Shen, Zhilin Liu, Miaozhou Wang, et al.Journal of Medicinal Chemistry|August 6, 2024
Development of VU6036864: A Triazolopyridine-Based High-Quality Antagonist Tool Compound of the M5 Muscarinic Acetylcholine ReceptorJinming Li, Douglas L Orsi, Julie L Engers, et al.Journal of Medicinal Chemistry|April 13, 2022
Development of VU6019650: A Potent, Highly Selective, and Systemically Active Orthosteric Antagonist of the M5 Muscarinic Acetylcholine Receptor for the Treatment of Opioid Use DisorderAaron T Garrison, Douglas L Orsi, Rory A Capstick, et al.Pageof 51